Skip to search formSkip to main contentSkip to account menu

Xtandi

National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

enzalutamide
enzalutamide 40 MG Oral Capsule [Xtandi]enzalutamide Oral Capsule [Xtandi]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) have never received androgen deprivation therapy (ADT) before… 
Review
2018
Review
2018
FDA Approves XTANDI ® ( enzalutamide ) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer ( CRPC ) Release Date :
  • 2018
  • Corpus ID: 52267912
TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and… 
2018
2018
Advances in radiotherapy for lung cancer
Článek přijat k publikaci: 8. 7. 2018 Zkrácená informace o léčivém přípravku XTANDI Název: Xtandi 40 mg měkké tobolky. Složení l… 
2018
2018
The role of FDG PET/CT in the management of malignant melanoma
Postavení FDG Pet/Ct v manaGementu maliGního melanomu Zkrácená informace o léčivém přípravku XTANDI. Název: Xtandi 40 mg měkk… 
2016
2016
Enzalutamide (Xtandi®) et interférence analytique lors du dosage de la digoxinémie
2015
2015
Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late‐Stage Prostate Cancer
2013
2013
Rational approach to Xtandi resistance
MSKCC researchers have identified a mutation in the androgen receptor that drives resistance to second-generation antiandrogen… 
2013
2013
Enzalutamide (Xtandi) for prostate cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)